21 May 2009
Extended criteria and NHB organ donation
F DelmonicoAnn Transplant 2009; 14(1): 19-19 :: ID: 880520
Abstract
An "expanded" criteria donor (ECD) kidney is defi ned in the United States by the Organ Procurement and Transplantation Network (OPTN) as a kidney re-covered from a deceased donor of age 60 years or greater, or a donor between 50 and 59 years of age who meets at least two of the following criteria: a terminal pre-recovery serum creatinine >1.5 mg/dl, a cerebrovascular accident as the cause of death, or a history of hypertension. Kidneys transplanted from an ECD have a relative risk (RR) of allograft failure that is ≥70% greater than that of kidneys transplanted from an "ideal" reference group of non-hypertensive deceased donors between the ages of 10 and 39 years with a terminal serum creatinine of less than 1.5 mg/dl and death from a cause other than a cerebral vascular accident. Since the inception of the ECD allocation system in 2002 there has been a national ECD kidney discard rate of 40%, significantly higher than the 9% discard rate observed for SCD kidneys. Non-recovery of ECD kidneys or discard of recovered ECD kidneys would be justified if the observed outcome for such kidneys was dramatically poor; but with the exception of kidneys from donors aged 70 years or older and percent GS >20%, a recently completed study data did not reveal any significant association between those characteristics that appear to contribute to the decision to discard an ECD kidney and post-transplant outcomes. Therefore, practice as it relates to discard often appears to be unjustified by actual transplant outcomes. There is an expansion of donation at the cardiac death in the United States attributed to changing societal attitude and practices in the intensive care unit that are leading to withdrawal of futile treatment before a brain death determination is made. The consequence of these developments has been a reduction in the eligible deceased organ donors in the United States.
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






